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Abstracts / Urological Science 27 (2016) S36eS52S48which resulted in smaller wounds and rapid recovery. This operation can
be performed using either transperitoneal or retroperitoneal techniques.
The advantages of retroperitoneal approach were avoidance of bowel
manipulation and it could be direct access to the kidney. Thus the aim of
our study was to evaluate the experience of laparoscopic retroperitoneo-
scopic partial nephrectomy for angiomyolipoma in our center.
Materials and Methods: We retrospectively analyzed the medical records
of 20 patients (17 females and 3 males) who underwent retroperitoneal
laparoscopic partial nephrectomies for benign renal tumor (pathology:
angiomyolipoma) in Chi-Mei Medical Center from June 2012 to July 2015.
All of the surgeries were performed by a single surgeon. The demographic
data, characteristic of tumors, peri-operative status and post-operative
outcome were analyzed.
Results: Twenty-two partial nephrectomies were performed in twenty-one
kidneys. The mean age was 48-year-old (27-70). Most of the patients were
diagnosed incidentally, only 4patients (20%) presentedwith the symptomof
ﬂank or abdominal pain. Themean size of tumorswhich disclosed by CTwas
4.9 cm (1-18). Meanwhile the R.E.N.A.L nephrometry score was 6.1 in
average. Only one patient who underwent pre-operative TAE due to huge
tumor size (18cm). There was a wide range of operative time with mean
176 mins (90-345) related to the complexity of tumors. The average warm
ischemic time was 9.4 mins (0-20.7) with 7 partial nephrectomies done in
zero-ischemia status. Intra-operative estimated blood loss 173 ml (10-600).
No major surgical complications noted. Only 3 patients required blood
transfusionperioperatively. Another one patient experienced asymptomatic
perirenal hematomaduringCT follow-up. Theaveragepost-operative length
of hospital stay was 3.3 days (2-8). Regarding the renal function, the average
decreased of GFRof lesion side after operationwas 11% (from 46.5ml/min to
41.4 ml/min). Two patients revealed residual tumors and one patients
showed tumor recurrence by CT during out-patient department follow-up.
Conclusion: Laparoscopic retroperitoneoscopic renal surgery can be per-
formed safely and effectively. However, the limited space of retro-
peritoneum given this procedure more challenging.
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Purpose: We describe the preliminary experience of a new method by
Thulium laser for transurethral resection of CIS or diffuse sessile bladder
tumors.
Materials and Methods: From September 2014 to December 2015, 7 pa-
tients (6 males and 1 female) newly diagnosed with having diffuse sessile
bladder tumors with or without ureteral oriﬁce involved were selected by
TUR-BT of Thulium Laser. A 10-20 watts Thulium laser power was used to
incise bladder tumors by 300-microm ﬁber through resectoscope. Mean
tumor diameter was 5.5cm (range 3.5e9.0)
Results: All patients were treated successfully in one secession. No pa-
tients experienced detrusor nerve reﬂection intra-operatively and no
bladder perforation in dome-located neoplasm. Mean operative time was
55 min (range 30e100). Tumors involved ureteral meatus were noted in 3
patients. The oriﬁce was sharply excised without subsequent evidence of
stenosis. The mean follow-up time was 8.4 months. Tumor recurrences
were found in two patients in 6 and 12 months postoperatively.
Conclusion: In our limited experience, Thulium laser TURBT is a reliable
therapy with minimal morbidity for selected patients of diffuse bladder
tumors with ureteral oriﬁce involved or CIS.
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Purpose: The etiology of chronic prostatitis/chronic pelvic pain syndrome
(CP/CPPS) is unknown, and there are still no established treatments that
consistently relieve patients' symptoms. Endocannabinoids serves as
important modulators of tissue inﬂammation and pain perception.
Manipulation of cannabinoid system had been shown to reduce inﬂam-
mation and lessen pain perception in some inﬂammatory disorders. This
study investigated the changes of cannabinoid system following capsaicin-
induced prostatitis in castrated and non-castrated rats.
Materials and Methods: In adult male Sprague-Dawley rats androgen
deprivation was induced with bilateral orchiectomy (OX). At 4 weeks after
bilateral OX or sham operation, prostate inﬂammation was induced by
intraprostatic capsaicin injection. Control group received intraprostatic
vehicle injection. The expression of cannabinoid receptor type 1(CB1) and
2(CB2), fatty amide hydrolase (FAAH) and cyclooxygenase 2(COX-2) in
each group were examined with RT-PCR for mRNA and
immunohistochemistry.
Results: Capsaicin injection induced an inﬂammatory reaction with inﬁl-
tration of leukocytes. Expression of COX-2 was enhanced following
capsaicin injection. Capsaicin injection increased CB2 expression, while
the expression of CB1 was not changed. Expression of FAAH, a endo-
cannabinoid degradation enzyme, was reduced following capsaicin in-
jection. Castration induced an atrophic change of the prostate gland.
Expression of CB1, CB2 and FAAH was enhanced following castration.
Capsaicin injection also induced an inﬂammatory reaction in the cas-
trated-prostate, but with a lesser degree of leukocyte accumulation as
compared with non-castrated group. In the castrated-prostate capsaicin
injection induced a further increase of CB2 expression, while expression of
CB1 and FAAH was not changed.
Conclusion: The present study demonstrated a consistent up-regulation
of CB2 following capsaicin-induced prostatitis in castrated and non-cas-
trated rats. CB2 can be a promising therapeutic target in treating non-
bacterial prostatitis.
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SAFETY AND THERAPEUTIC EFFICACY OF MIRABEGRON 25 MG IN VERY
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Purpose: To assess the therapeutic efﬁcacy and safety of mirabegron
25 mg once daily in very old and frail patients with overactive bladder
(OAB) and multiple comorbidities compared with younger patients.
Materials and Methods: Patients with OAB at the age range of between
twenty to sixty years old and over eighty years old were included in this
study. All of the participants were treatment-naive or no treatment more 3
months at the baseline, treated with mirabegron 25 mg once daily. The
patients were divided into two groups, younger (20-60 years old) and
older(S 80 years old). Patients who discontinued mirabegron 25 mg once
daily; or changed the dosage of mirabegron; or changed to antimuscarinics
during treatment course were excluded. Their underlying comorbidities
was recorded. Assessment tools included International Prostate Symptom
Score (IPSS), Overactive Bladder Symptom Score (OABSS), Urgency Severity
Score (USS), Patient Perception of Bladder Condition (PPBC), Quality of Life
(QoL), uroﬂowmetry and prostate volume. We compared the difference of
the change from baseline to 1st month and 3rd month between two groups.
Safety assessments included reporting adverse events (AEs) and post-void
residual.
Results: Total 92 patients (younger, N¼56; very older, N¼40) with OAB
treated with mirabegron 25 mg once daily were included. The mean age of
younger group was 50.55 ± 10.12 and older group was 85.58 ± 3.76. In
overall, the patients in the older group have more underlying comorbid-
ities than younger group (59 vs 30). There was no signiﬁcant difference of
baseline in IPSS, OABSS, USS, QoL and total prostate volume (TPV) between
two groups. However, the baseline Qmax, voided volume, post-voided
residual (PVR) and PPBC were lower in older group. A statistically
